Semaglutide (active ingredient in Ozempic and Wegovy) and tirzepatide (active ingredient in Mounjaro and Zepbound) are in a class of medications called glucagon-like peptide 1 (GLP-1) agonists. This mimics the incretin hormone GLP-1 found naturally in our bodies. GLP-1 agonists work by stimulating your pancreas to increase insulin, slows gastric emptying, and sends signals to your brain telling you that you are full. This process makes these medications a powerful appetite suppressant

Tirzepatide is unique because it is the first dual action drug in its class. It acts as a GLP-1 agonist (as stated above) and a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. GLP-1 and GIP are both incretin hormones that are released after eating. Tirzepatide works by mimicking their effects including telling the pancreas to release insulin after eating and signaling the liver to lower the amount of glucose it is making which helps lower blood sugar.

Tirzepatide also has a lower incidence of certain known side effects, including nausea. It is currently the MOST effective weight loss medication available.

Yes, both of these medications have been evaluated extensively and approved by the FDA.

The most common side effect is nausea. Other side effects that can occur are vomiting, diarrhea, abdominal pain and constipation.

We will care for patients that are 18 years or older.

It is not recommended to take these medications if you have any of the following:

• Type 1 Diabetes

• History of pancreatitis

• Gastroparesis (slow gastric emptying) or other severe GI conditions

• Personal or family history of medullary thyroid cancer

• Hypersensitivity to semaglutide or tirzepatide

• Pregnant or breastfeeding

• End stage kidney disease

• BMI <25

Both medications are injected with a small subcutaneous needle in the abdomen, thigh, or upper arm ONCE weekly, on the same day each week, at any time of day, with or without meals.

*We have nurses that can help administer this injection weekly if you need assistance.